Same Dosages of rPRV/XJ5-gI-/gE-/TK- Prototype Vaccine or Bartha-K61 Vaccine Similarly Protects Growing Pigs Against Lethal Challenge of Emerging vPRV/XJ-5 Strain

Variant pseudorabies viruses (vPRV) have constantly emerged in China since late 2011. In the present study, a 1 x 10(6.0) TCID50 per-animal dosage of a commercially available Bartha-K61 vaccine and an rPRV/XJ5-gI(-)/gE(-)/TK- prototype vaccine freshly extracted from the vPRV/XJ-5 at the same dose were administered to evaluate the immune effectiveness thereof on growing pigs to prevent lethal strikes caused by vPRV/XJ-5. The results suggest that the Bartha-K61 vaccine at a dose of 1 x 10(6.0) TCID50 per animal and the same dosage of the rPRV/XJ5-gI(-)/gE(-)/TK- prototype vaccine protected growing pigs against the lethal challenge of vPRV/XJ-5 strain with 100% survive rate. Furthermore, the outcome of the clinical score, virus shedding, weight gain, and viral loads in different pig tissues in these two groups demonstrates that either the Bartha-K61 vaccine or the rPRV/XJ5-gI(-)/gE(-)/TK- prototype vaccine at the same dose exhibited parallel efficacy in pigs against the lethal challenge with the XJ-5 strain of vPRV.

Automated summary

The immune effectiveness of Bartha-K61 vaccine and rPRV/XJ5-gI(-)/gE(-)/TK- prototype vaccine against vPRV/XJ-5 was evaluated in growing pigs. The results demonstrated that both vaccines provided parallel efficacy in pigs against the lethal challenge with the XJ-5 strain of vPRV.